Brand Institute's AI-Developed Pharmaceutical Name Receives EMA Approval

This milestone represents the first time an AI-generated brand name has been approved by a major global regulatory authority.

Apr. 17, 2026 at 6:22pm

Got story updates? Submit your updates here. ›

A highly detailed, glowing 3D illustration of a futuristic pharmaceutical pill capsule with intricate internal mechanisms, suspended against a dark background and illuminated by neon cyan and magenta lights, conceptually representing the advanced technology and regulatory rigor behind an AI-developed brand name.An AI-powered pharmaceutical brand name navigates the complex regulatory landscape, illuminating the future of drug development.Today in Miami

Brand Institute, a global leader in pharmaceutical and healthcare-related name development, announced that the European Medicines Agency (EMA) has approved a pharmaceutical product brand name developed using the company's proprietary AI-powered name generation platform, Brandi. This marks the first time in Brand Institute's history that a brand name created with the support of its artificial intelligence technology has received approval from a major regulatory agency.

Why it matters

This achievement underscores Brand Institute's continued leadership in pharmaceutical and healthcare naming, as well as its commitment to advancing innovation in a field defined by increasingly stringent regulatory standards and competitive pressures. It also demonstrates the potential for AI-enabled naming solutions to meet the complex and highly specific requirements of global regulatory bodies.

The details

The approved brand name will be publicly disclosed following EMA approval of the corresponding pharmaceutical product. This reflects standard regulatory practice, in which brand names are reviewed in advance to ensure they meet regulatory requirements and are ready for use once the medicine receives final authorization. The name was developed through a collaborative process that integrates Brand Institute's strategic expertise with Brandi's advanced generative capabilities.

  • Brand Institute announced the EMA approval on April 17, 2026.

The players

Brand Institute

A global leader in pharmaceutical and healthcare-related name development, providing a full suite of services including brand name creation, trademark screening, regulatory strategy, and market research.

Brandi

Brand Institute's proprietary AI-powered name generation platform.

European Medicines Agency (EMA)

The regulatory authority that approved the pharmaceutical brand name developed using Brand Institute's AI technology.

James L. Dettore

Brand Institute's Founder, Chairman and Chief Executive Officer.

Scott Piergrossi

Brand Institute's President of Creative.

Got photos? Submit your photos here. ›

What they’re saying

“This moment represents a meaningful inflection point not only for Brand Institute, but for the future of pharmaceutical naming.”

— James L. Dettore, Founder, Chairman and Chief Executive Officer, Brand Institute

“We couldn't be more excited that an AI-co-created name has been approved by the EMA.”

— Scott Piergrossi, President of Creative, Brand Institute

What’s next

The approved brand name will be publicly disclosed following EMA approval of the corresponding pharmaceutical product.

The takeaway

This achievement demonstrates the potential for AI-enabled naming solutions to meet the complex and highly specific requirements of global regulatory bodies in the pharmaceutical industry, while also highlighting Brand Institute's continued leadership in this specialized field.